SCHEMBL30737799

SCHEMBL30737799

COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(CCN(C)C)C(C)=O)cc1)c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SENP1 Q9P0U3 1/20 0.38
KMT2A Q03164 4/20 0.36
MEN1 O00255 3/20 0.36
CTDSP1 Q9GZU7 1/20 0.36
BACE1 P56817 2/20 0.36
CASP1 P29466 1/20 0.35
TP53 P04637 2/20 0.35
POLB P06746 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
THRB P10828 1/20 0.35
BLM P54132 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
RAB9A P51151 3/20 0.35
ALDH1A1 P00352 3/20 0.35
MAPT P10636 2/20 0.35
LMNA P02545 1/20 0.35
NPC1 O15118 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
PTPN1 P18031 1/20 0.34
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2571801 1.00 SENP1 (0.38) SENP1KMT2AMEN1CTDSP1BACE1
SCHEMBL2571796 1.00 SENP1 (0.38) SENP1KMT2AMEN1CTDSP1BACE1
SCHEMBL30737878 0.95 SENP1 (0.37) SENP1KMT2AMEN1CTDSP1BACE1
SCHEMBL436186 0.95 SENP1 (0.37) SENP1KMT2AMEN1CTDSP1BACE1
SCHEMBL436187 0.95 SENP1 (0.37) SENP1KMT2AMEN1CTDSP1BACE1
SCHEMBL2571630 0.93 SENP1 (0.38) SENP1KMT2AMEN1CTDSP1BACE1
SCHEMBL2571633 0.93 SENP1 (0.38) SENP1KMT2AMEN1CTDSP1BACE1
SCHEMBL31094012 0.93 RXFP1 (0.43) SENP1KMT2AMEN1TP53POLB
SCHEMBL2567836 0.93 RXFP1 (0.43) SENP1KMT2AMEN1TP53POLB
SCHEMBL2567839 0.93 RXFP1 (0.43) SENP1KMT2AMEN1TP53POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023240271-A1 USE OF VEGFR2 AND FGFR1 INHIBITORS IN THERAPY FOUNTAIN THERAPEUTICS INC. (US) 2023-12-14 WO claimed
CN-112004527-B Inhalable liposome sustained release compositions for treating pulmonary diseases 盈擘生技股份有限公司 2024-09-24 CN disclosed
WO-2023240271-A1 USE OF VEGFR2 AND FGFR1 INHIBITORS IN THERAPY FOUNTAIN THERAPEUTICS INC. (US) 2023-12-14 WO disclosed